# Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

> **NCT01847001** · PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 10 (actual)

## Conditions studied

- Locally Advanced Malignant Neoplasm
- Breast Cancer

## Interventions

- **DRUG:** Propranolol
- **OTHER:** DOT imaging
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Surgery
- **DRUG:** Premedication
- **DRUG:** Anti-nausea therapy
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01847001
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-10-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847001, "Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01847001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*